These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15264106)

  • 1. Immunogenicity of recombinant human proteins: causes and consequences.
    Schellekens H; Casadevall N
    J Neurol; 2004 Jun; 251 Suppl 2():II4-9. PubMed ID: 15264106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No antibodies to granulocyte macrophage colony-stimulating factor with prolonged use in AIDS.
    Scadden DT; Agosti J
    AIDS; 1993 Mar; 7(3):438. PubMed ID: 8471211
    [No Abstract]   [Full Text] [Related]  

  • 3. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis.
    Bourantas KL; Tsiara S; Christou L; Repousis P; Konstantinidou P; Bai M; Seferiadis K
    Acta Haematol; 1996; 96(2):79-82. PubMed ID: 8701705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
    Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
    [No Abstract]   [Full Text] [Related]  

  • 6. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
    Lusher JM; Arkin S; Abildgaard CF; Schwartz RS
    N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing.
    Mytych DT; Barger TE; King C; Grauer S; Haldankar R; Hsu E; Wu MM; Shiwalkar M; Sanchez S; Kuck A; Civoli F; Sun J; Swanson SJ
    J Immunol Methods; 2012 Aug; 382(1-2):129-41. PubMed ID: 22634015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.
    Oldenburg J; Lacroix-Desmazes S; Lillicrap D
    Haematologica; 2015 Feb; 100(2):149-56. PubMed ID: 25638804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-mediated side effects of recombinant proteins.
    Frost H
    Toxicology; 2005 Apr; 209(2):155-60. PubMed ID: 15767028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An immunodominant epitope in a functional domain near the N-terminus of human granulocyte-macrophage colony-stimulating factor identified by cross-reaction of synthetic peptides with neutralizing anti-protein and anti-peptide antibodies.
    Beffy P; Rovero P; Di Bartolo V; Laricchia Robbio L; Dané A; Pegoraro S; Bertolero F; Revoltella RP
    Hybridoma; 1994 Dec; 13(6):457-68. PubMed ID: 7737670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF).
    Rini B; Wadhwa M; Bird C; Small E; Gaines-Das R; Thorpe R
    Cytokine; 2005 Jan; 29(2):56-66. PubMed ID: 15598439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.
    Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
    Biopharm Drug Dispos; 2016 Oct; 37(7):409-420. PubMed ID: 27418232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII.
    Lollar P
    Thromb Haemost; 1997 Jul; 78(1):647-51. PubMed ID: 9198232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody response to recombinant human coagulation factor VIII in a new rat model of severe hemophilia A.
    Lövgren KM; Søndergaard H; Skov S; Weldingh KN; Tranholm M; Wiinberg B
    J Thromb Haemost; 2016 Apr; 14(4):747-56. PubMed ID: 26784374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII inhibitors.
    Gilles JG; Jacquemin MG; Saint-Remy JM
    Thromb Haemost; 1997 Jul; 78(1):641-6. PubMed ID: 9198231
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunological mechanism underlying the immune response to recombinant human protein therapeutics.
    Sauerborn M; Brinks V; Jiskoot W; Schellekens H
    Trends Pharmacol Sci; 2010 Feb; 31(2):53-9. PubMed ID: 19963283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid elimination of a high-titered F VIII inhibitor by high dose recombinant F VIII combined with high dose immunoglobulin infusion.
    Mauz-Korholz C; Korholz D; Gobel U
    Thromb Haemost; 1997 Aug; 78(2):959. PubMed ID: 9268203
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of recombinant human tumor necrosis factor alpha, recombinant human gamma-interferon, and prostaglandin E on colony formation of human hematopoietic progenitor cells stimulated by natural human pluripotent colony-stimulating factor, pluripoietin alpha, and recombinant erythropoietin in serum-free cultures.
    Lu L; Welte K; Gabrilove JL; Hangoc G; Bruno E; Hoffman R; Broxmeyer HE
    Cancer Res; 1986 Sep; 46(9):4357-61. PubMed ID: 3089590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
    Monahan PE; Aledort LM;
    Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.